<DOC>
	<DOCNO>NCT00365794</DOCNO>
	<brief_summary>A . HYPOTHESES : In old men low testosterone level , abdominal obesity elevate fasting insulin risk cardiovascular complication heart attack stroke . 1 . Supplemental testosterone decrease abdominal fat ( visceral adominal adipose tissue ( VAT ) , subcutaneous abdominal adipose tissue ( SAT ) , hepatic fat ) intramyocellular lipid peripheral muscle ( IMCL ) . 2 . Supplemental testosterone improve insulin sensitivity : 1 . Decreasing hepatic glucose output ( HGO ) , measure central insulin resistance 2 . Decreasing VAT 3 . Decreasing SAT 4 . Increasing adiponectin production 5 . Improving peripheral glucose disposal ( Rd ) reduce IMCL 6 . Increasing appendicular skeletal muscle mass basal metabolic rate B . OBJECTIVES : 1 . Primary Objective : To determine effect supplemental testosterone achieve testosterone level upper normal physiologic range central adipose tissue ( abdominal VAT , SAT , hepatic fat ) peripheral skeletal muscle fat ( IMCL intermyocellular fat ) . 2 . Secondary Objectives : To determine effect supplemental testosterone achieve testosterone level upper normal physiologic range : 1. hepatic glucose output ( HGO ) peripheral glucose disposal ( Rd ) 2. hepatic glucose synthesis glycogen , glycerol Krebs cycle use [ 1,6-13C2C ] glucose , D2O , [ U-13C3 ] palmitate isotope dilution study 3. adiponectin apoprotein B level 4. basal metabolic rate ( REE , R/Q ) relate change skeletal muscle mass Results study provide great understand whether androgen therapy enhance insulin sensitivity decrease HGO , decrease adiponectin production , improve peripheral Rd desire effect achieve , whether due reduction VAT , SAT , liver fat , IMCL effect augment muscle mass per se . Results generate hypothesis investigate cellular molecular mechanism androgen effect person risk Metabolic Syndrome .</brief_summary>
	<brief_title>Investigator Initiated Study Effects Androgen Therapy Carbohydrate Lipid Metabolism In Elderly Men</brief_title>
	<detailed_description>Study Design : This investigator-initiated open label , study investigate effect supplemental testosterone increase testosterone level upper normal range 12 old hypogonadal ( testosterone level less 300 ng/dL ) men abdominal obesity elevate fasting insulin level . Subjects assign receive 10 g transdermal testosterone ( Androgel ) every morning achieve level upper normal physiologic range ( similar men 3rd 4th decade ) 20 week . - For primary objective , regional adipose tissue , namely abdominal VAT , abdominal SAT , hepatic fat , IMCL image MRI 1H-spectroscopy baseline ( study week 0 ) study week 20 ( completion study therapy ) . - For secondary objective , insulin sensitivity ( peripheral Rd , hepatic glucose output [ HGO ] ) hepatic gluconeogenesis measure directly two stage hyperinsulinemic euglycemic clamp baseline study week 20 . - Indirect marker lipid ( adiponectin , ApoB 100 ) carbohydrate metabolism ( Fasting blood sugar , HOMA-IR , QUICKI ) along DEXA analysis regional adipose appendicular lean tissue ( mainly skeletal muscle ) measure baseline , study week 10 , study week 20 . All component study conduct USC NIH-funded ( NCRR ) , General Clinical Research Center .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Entry Criteria : Men &gt; 60 year age Total testosterone &lt; 300 ng/dL Waist circumference &gt; 102 cm Fasting insulin level &gt; 18 U/L PSA &gt; 4.1 , symptom obstructive uropathy ( AUA score &gt; 14 ) , unexplained prostate nodule gland firmness Hematocrit &gt; 50 % Malignancy cutaneous cancer Sleep apnea require CPAP History myocardial infarction , angina stroke within previous 6 month Clinical diagnosis diabetes FPG &gt; 126 mg/dL Hypothyroidism control euthyroid level medication least 3 month LDLC &gt; 160 mg/dL Transaminases &gt; 1.5X ULN Systemic anticoagulation warfarin Active progressive resistance training Dieting weight loss Active inflammatory condition ( e.g . rheumatoid arthritis ) Use anabolic agent ( e.g . growth hormone , testosterone precursor , anabolic steroid ) cytokine therapy proceed 12 month</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Aging</keyword>
	<keyword>Older men</keyword>
	<keyword>Abdominal obesity</keyword>
	<keyword>Central obesity</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Low testosterone</keyword>
</DOC>